Cited by 2,833Heart Failure Treatment and ManagementHeart rate and cardiovascular healthCardiovascular Function and Risk Factors

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

Open access

Cohn, Jay N., Johnson, Gary, Ziesche, Susan, Cobb, Frederick, Francis, Gary, Tristani, Felix, Smith, Raphael, Dunkman, W. Bruce, Loeb, Henry, Wong, Maylene, Bhat, Geetha, Goldman, Steven, Fletcher, Ross D., Doherty, James, Hughes, C. Vincent, Carson, Peter, Cintron, Guillermo, Shabetai, Ralph, Haakenson, Clair·1991·New England Journal of Medicine

DOI 10.1056/nejm199108013250502

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: To define better the efficacy of vasodilator therapy in the treatment of chronic congestive heart failure, we compared the effects of hydralazine and isosorbide dinitrate with those of enalapril in 804 men receiving digoxin and diuretic therapy for heart failure. The patients were randomly assigned in a double-blind manner to receive 20 mg of enalapril daily or 300 mg of hydralazine plus 160 mg of isosorbide dinitrate daily. The latter regimen was identical to that used with a similar patient population in the effective-treatment arm of our previous Vasodilator-Heart Failure Trial. RESULTS: Mortality after two years was significantly lower in the enalapril arm (18 percent) than in the hydralazine-isosorbide dinitrate arm (25 percent) (P = 0.016; reduction in mortality, 28.0 percent), and overall mortality tended to be lower (P = 0.08). The lower mortality in the enalapril arm was attributable to a reduction in the incidence of sudden death, and this beneficial effect was more prominent in patients with less severe symptoms (New York Heart Association class I or II). In contrast, body oxygen consumption at peak exercise was increased only by hydralazine-isosorbide dinitrate treatment (P less than 0.05), and left ventricular ejection fraction, which increased with both regimens during the 2 years after randomization, increased more (P less than 0.05) during the first 13 weeks in the hydralazine-isosorbide dinitrate group. CONCLUSIONS: The similar two-year mortality in the hydralazine-isosorbide dinitrate arms in our previous Vasodilator-Heart Failure Trial (26 percent) and in the present trial (25 percent), as compared with that in the placebo arm in the previous trial, (34 percent) and the further survival benefit with enalapril in the present trial (18 percent) strengthen the conclusion that vasodilator therapy should be included in the standard treatment for heart failure. The different effects of the two regimens (enalapril and hydralazine-isosorbide dinitrate) on mortality and physiologic end points suggest that the profile of effects might be enhanced if the regimens were used in combination.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199108013250502

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,109
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure
Cohn, J. N., Archibald, D. G., Ziesche, S., Franciosa, J. A., Harston, W. E., Tristani, F. E., Dunkman, W. B., Jacobs, W., Francis, G. S., Flohr, K. H., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606123142404 · Cited by 2,400
Self-citation
A placebo-controlled trial of captopril in refractory chronic congestive heart failure
Captopril Multicenter Research Group (1983) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(83)80316-7 · Cited by 588
Vasodilator Therapy of Cardiac Failure
Cohn, J. N., & Franciosa, J. A. (1977) · New England Journal of Medicine · doi:10.1056/nejm197707072970105 · Cited by 483
Self-citation
The role of vasodilator therapy in heart failure
Chatterjee, K., & Parmley, W. W. (1977) · Progress in Cardiovascular Diseases · doi:10.1016/0033-0620(77)90006-8 · Cited by 315
Vasodilator Therapy for Heart Failure
Cohn, J. N. (1973) · Circulation · doi:10.1161/01.cir.48.1.5 · Cited by 293
Self-citation
Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure.
Leier, C. V., Huss, P., Magorien, R. D., & Unverferth, D. V. (1983) · Circulation · doi:10.1161/01.cir.67.4.817 · Cited by 289

Show all 19 references

Research works printed but not linked: 1

Cohn, 1987, Circulation, 76, IV–443

Sorted by citations

Items 701–800 of 1,000

Failing ageing hearts
Petrie, M. C. (2001) · European Heart Journal · doi:10.1053/euhj.2000.2558 · Cited by 43
Comparison of the acute effects of a selective endothelin ETA and a mixed ETA/ETB receptor antagonist in heart failure
Ohnishi, M. (1998) · Cardiovascular Research · doi:10.1016/s0008-6363(98)00205-3 · Cited by 43
Tolerability of enalapril initiation by patients with left ventricular dysfunction: Results of the medication challenge phase of the studies of left ventricular dysfunction
Kostis, J. B., Shelton, B. J., Yusuf, S., Weiss, M. B., Capone, R. J., Pepine, C. J., Gosselin, G., Delahaye, F., Probstfield, J. L., Cahill, L., et al. (1994) · American Heart Journal · doi:10.1016/0002-8703(94)90490-1 · Cited by 43
Heart failure between 1986 and 1994: Temporal trends in drug-prescribing practices, hospital readmissions, and survival at an academic medical center
McDermott, M. M., Feinglass, J. M., Lee, P. J., Mehta, S. H., Schmitt, B. P., Lefevre, F., Puppala, J., & Gheorghiade, M. (1997) · American Heart Journal · doi:10.1016/s0002-8703(97)80013-0 · Cited by 43
Organic nitrates in cardiovascular disease.
Bode‐Böger, S. M., & Kojda, G. (2005) · PubMed · Cited by 42
Bioactivation of organic nitrates and the mechanism of nitrate tolerance.
Klemenska, E., & Berȩsewicz, A. (2009) · PubMed · Cited by 42
Selection of Endpoints for Heart Failure Clinical Trials
Zanolla, L., & Zardini, P. (2003) · European Journal of Heart Failure · doi:10.1016/s1388-9842(03)00101-6 · Cited by 42
Current and future G protein-coupled receptor signaling targets for heart failure therapy
Lymperopoulos, A., Siryk, A., & Dabul, S. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s35905 · Cited by 44
Heart Failure due to Ischaemic Heart Disease: Epidemiology, Pathophysiology and Progression
Cleland, J. G. F., & McGowan, J. (1999) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199906003-00003 · Cited by 42
[Task Force on Sudden Cardiac Death, European Society of Cardiology. Summary of recommendations].
Priori, S. G., Aliot, E., Blomström‐Lundqvist, C., Bossaert, L. L., Breithardt, G., Brugada, P., Camm, A. J., Cappato, R., Cobbe, S. M., Mario, C. D., et al. (2002) · PubMed · Cited by 42
Continuous ambulatory haemodynamic monitoring with an implantable system The feasibility of a new technique
Ohlsson, A. (1998) · European Heart Journal · doi:10.1053/euhj.1997.0563 · Cited by 42
Congestive heart failure and pulmonary edema for the emergency physician
Fromm, R. E., Varón, J., & Gibbs, L. R. (1995) · Journal of Emergency Medicine · doi:10.1016/0736-4679(94)00125-1 · Cited by 43
Barriers to optimum management of heart failure by general practitioners.
Horne, R., Coombes, I., Davies, G., Hankins, M. C., & Vincent, R. (1999) · Europe PMC (PubMed Central) · Cited by 42
Serial exercise testing and prognosis in selected patients considered for cardiac transplantation
Gullestad, L. L., MYERS, J. N., Ross, H. J., Rickenbacher, P. R., Slauson, S., Bellin, D., Do, D., Vagelos, R. H., & Fowler, M. B. (1998) · American Heart Journal · doi:10.1016/s0002-8703(98)70085-7 · Cited by 42
Effects of ACE Inhibitors on Heart Failure in The Netherlands
van Hout, B. A., Wielink, G., Bonsel, G. J., & Rutten, F. (1993) · PharmacoEconomics · doi:10.2165/00019053-199303050-00006 · Cited by 42
Calcium sensitisers: mechanisms of action and potential usefulness as inotropes
Lee, J. A., & Allen, D. G. (1997) · Cardiovascular Research · doi:10.1016/s0008-6363(97)00174-0 · Cited by 42
Is optimal angiotensin-converting enzyme inhibitor dosing neglected in elderly patients with heart failure?
Gattis, W. A., Larsen, R. L., Hasselblad, V., Bart, B. A., & O’Connor, C. M. (1998) · American Heart Journal · doi:10.1016/s0002-8703(98)70180-2 · Cited by 42
Angiotensin II receptor antagonists in heart failure: Rationale and design of the evaluation of losartan in the elderly (ELITE) trial
Pitt, B., Chang, P., & Timmermans, P. B. M. W. M. (1995) · Cardiovascular Drugs and Therapy · doi:10.1007/bf00878552 · Cited by 42
Temporal trends in pharmacotherapy for congestive heart failure at an academic medical center: 1990-1995
Rich, M. W., Brooks, K., & Luthera, P. (1998) · American Heart Journal · doi:10.1016/s0002-8703(98)70309-6 · Cited by 42
Mechanisms of Remodelling A Question of Life (Stem Cell Production) and Death (Myocyte Apoptosis)
Ferrari, R., Ceconi, C., Campo, G. C., Cangiano, E., Cavazza, C., Secchiero, P., & Tavazzi, L. (2009) · Circulation Journal · doi:10.1253/circj.cj-09-0573 · Cited by 41
Office management of heart failure in the elderly
Rich, M. W. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.12.019 · Cited by 41
Hemodynamic responses to small muscle mass exercise in heart failure patients with reduced ejection fraction
Barrett‐O’Keefe, Z., Lee, J. F., Berbert, A., Witman, M. A., Nativi-Nicolau, J. N., Stehlik, J., Richardson, R. S., & Wray, D. W. (2014) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00527.2014 · Cited by 41
Use of Hydralazine‐Isosorbide Dinitrate Combination in African American and Other Race/Ethnic Group Patients With Heart Failure and Reduced Left Ventricular Ejection Fraction
Golwala, H. B., Thadani, U., Liang, L., Stavrakis, S., Butler, J., Yancy, C. W., Bhatt, D. L., Hernandez, A. F., & Fonarow, G. C. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000214 · Cited by 42
Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition
Newby, D. E., McDonagh, T., Currie, P. F., Northridge, D. B., Boon, N. A., & Dargie, H. J. (1998) · European Heart Journal · doi:10.1053/euhj.1998.1201 · Cited by 41
Increased D allele frequency of the angiotensin-converting enzyme gene in pulmonary fibrosis
Morrison, C. D., Papp, A. C., Hejmanowski, A. Q., Addis, V. M., & Prior, T. W. (2001) · Human Pathology · doi:10.1053/hupa.2001.24321 · Cited by 41
Cardiovascular Drug Therapy in the Elderly
Aronow, W. S., Frishman, W. H., & Cheng-Lai, A. (2007) · Cardiology in Review · doi:10.1097/crd.0b013e3180301b69 · Cited by 41
Angiotensin‐Converting Enzyme Inhibitor Use in Older Patients with Heart Failure and Renal Dysfunction
Philbin, E. F., Santella, R. N., & Rocco, T. A. (1999) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1999.tb02993.x · Cited by 41
Management and outcomes of congestive heart failure: a prospective study of hospitalised patients
LOWE, J. M., Candlish, P., Henry, D. A., Wlodarcyk, J. H., Heller, R. F., & Fletcher, P. (1998) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1998.tb126744.x · Cited by 41
Review article: Diabetes mellitus and heart failure — an overview of epidemiology and management
Baliga, V., & Sapsford, R. J. (2009) · Diabetes and Vascular Disease Research · doi:10.1177/1479164109338773 · Cited by 40
Racial Differences in the Characteristics of Patients Admitted for Acute Decompensated Heart Failure and Their Relation to Outcomes: Results From the OPTIME-CHF Trial
Echols, M. R., Felker, G. M., Thomas, K. L., Pieper, K. S., Garg, J., Cuffe, M. S., Gheorghiade, M., Califf, R. M., & O’Connor, C. M. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.003 · Cited by 42
Cancer Mortality in Trials of Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta‐Analysis
Tini, G., Bertero, E., Signori, A., Sormani, M. P., Maack, C., de Boer, R. A., Canepa, M., & Ameri, P. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.016309 · Cited by 40
Classification of Sudden and Arrhythmic Death
Torp-Pedersen, C. T., Køber, L., Elming, H., & Burchart, H. (1997) · Pacing and Clinical Electrophysiology · doi:10.1111/j.1540-8159.1997.tb06103.x · Cited by 40
EXPERT CONSENSUS DOCUMENT ON ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE
Lopez-Sendon, J., Swedberg, K. B., McMurray, J. J. V., Tamargo, J. L., Maggioni, A. P., Dargie, H., Tendera, M., Waagstein, F., Kjekshus, J., Lechat, P. P., et al. (2005) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2005-1-1-49-69 · Cited by 40
Rationale and Design of a Randomized Trial to Assess the Effects of β-blocker in Diastolic Heart Failure; Japanese Diastolic Heart Failure Study (J-DHF)
Hori, M., Kitabatake, A., Tsutsui, H., Okamoto, H., Shirato, K., Nagai, R., Izumi, T., Yokoyama, H., Yasumura, Y., Ishida, Y., et al. (2005) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2005.04.003 · Cited by 40
Hydralazine-induced vasodilation involves opening of high conductance Ca2+-activated K+ channels
Bang, L., Nielsen‐Kudsk, J. E., Gruhn, N., Trautner, S., Theilgaard, S. A., Olesen, S., Boesgaard, S., & Aldershvile, J. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00701-8 · Cited by 40
Regional differences in the characteristics and treatment of patients participating in an international heart failure trial
Massie, B. M., Cleland, J. G. F., Armstrong, P. W., Packer, M., Poole-Wilson, P. A., & Lars, R. (1998) · Journal of Cardiac Failure · doi:10.1016/s1071-9164(98)90502-4 · Cited by 40
ACE Inhibition versus Angiotensin Receptor Blockade
Laverman, G. D., Remuzzi, G., & Ruggenenti, P. L. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000093368.27046.3c · Cited by 40
Anticoagulation in patients with dilated cardiomyopathy and sinus rhythm: A critical literature review
Sirajuddin, R., Miller, A. B., & Geraci, S. A. (2002) · Journal of Cardiac Failure · doi:10.1054/jcaf.2002.31907 · Cited by 40
Does Aspirin Interfere with the Therapeutic Efficacy of Angiotensin‐converting Enzyme Inhibitors in Hypertension or Congestive Heart Failure?
Nawarskas, J. J., & Spinler, S. A. (1998) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1998.tb03933.x · Cited by 40
Differing Early Blood Pressure and Renin-Angiotensin System Responses to the First Dose of Angiotensin-Converting Enzyme Inhibitors in Congestive Heart Failure
Squire, I. B., MacFadyen, R. J., Reid, J. L., Devlin, A. M., & Lees, K. R. (1996) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199605000-00007 · Cited by 40
Long-Term Captopril Treatment Improves Diastolic Filling More Than Systolic Performance in Rats With Large Myocardial Infarction
Litwin, S. E., Katz, S. E., Morgan, J. P., & Douglas, P. S. (1996) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(96)00215-x · Cited by 40
Effect of Angiotensin-Converting Enzyme Inhibitors and Receptor Blockers on Appropriate Implantable Cardiac Defibrillator Shock in Patients With Severe Systolic Heart Failure (from the GRADE Multicenter Study)
AlJaroudi, W. A., Refaat, M. M., Habib, R., Al‐Shaar, L., Singh, M., Gutmann, R. A., Bloom, H. L., Dudley, S. C., Ellinor, P. T., Saba, S., et al. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.01.020 · Cited by 39
Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review
King, J. B., Bress, A. P., Reese, A. D., & Munger, M. A. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1629 · Cited by 43
Clinical Effectiveness of Hydralazine–Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure Registry
Khazanie, P., Liang, L., Curtis, L. H., Butler, J., Eapen, Z. J., Heidenreich, P. A., Bhatt, D. L., Peterson, E. D., Yancy, C. W., Fonarow, G. C., et al. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.002444 · Cited by 39
Novel Cardiac Intracrine Mechanisms Based on Ang-(1-12)/Chymase Axis Require a Revision of Therapeutic Approaches in Human Heart Disease
Reyes, S., Varagić, J., Ahmad, S., VonCannon, J. L., Kon, N. D., Wang, H., Groban, L., Cheng, C. P., Dell’Italia, L. J., & Ferrario, C. M. (2017) · Current Hypertension Reports · doi:10.1007/s11906-017-0708-3 · Cited by 39
Racial Differences in Responses to Drug Treatment
Taylor, J. S. W., & Ellis, G. R. (2002) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200202060-00004 · Cited by 39
The Practitioner's Dilemma: Can We Use a Patient's Race To Predict Genetics, Ancestry, and the Expected Outcomes of Treatment?
Barr, D. A. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-11-200512060-00009 · Cited by 39
The Natural History, Epidemiology, and Prognosis of Heart Failure in African Americans
Yancy, C. W., & Strong, M. A. (2004) · Congestive Heart Failure · doi:10.1111/j.1527-5299.2004.02026.x · Cited by 39
Antihypertensive Drugs and the Sympathetic Nervous System
Wenzel, R. R., Bruck, H., Noll, G., fers, R. F. S., Daul, A., & Philipp, T. (2000) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200000004-00006 · Cited by 39
Splanchnic Venous Pressure–Volume Relation During Experimental Acute Ischemic Heart Failure
Wang, S. Y., Manyari, D. E., Scott‐Douglas, N., Smiseth, O. A., Smith, E. R., & Tyberg, J. V. (1995) · Circulation · doi:10.1161/01.cir.91.4.1205 · Cited by 39
New Perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) I: Endogenous Angiotensin Converting Enzyme (ACE) Inhibition
Fagyas, M., Katalin, Ú., Siket, I. M., Daragó, A., Boczán, J., Bányai, E., Edes, I. F., Papp, Z., & Tóth, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087843 · Cited by 39
Should general practitioners use the electrocardiogram to select patients with suspected heart failure for echocardiography?
Houghton, A. R., Sparrow, N., Toms, E., & Cowley, A. J. (1997) · International Journal of Cardiology · doi:10.1016/s0167-5273(97)00181-2 · Cited by 39
BNP in hormone-guided treatment of heart failure
Richards, M., Lainchbury, J. G., Nicholls, M. G., Troughton, R. W., & Yandle, T. G. (2002) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(01)00554-9 · Cited by 39
Effects of enalapril on heart rate variability in patients with congestive heart failure
Zhang, Y., Song, Y.-H., Zhu, J., Hu, T., & Wan, L.-L. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80294-x · Cited by 39
Guías de práctica clínica de la Sociedad Española de Cardiología en miocardiopatías y miocarditis
Basilio, E. G., Manterola, F. A., Rodes, M., Beiras, A. C., Pantoja, R. F. D. S., Lado, M. P., & Domínguez, J. S. (2000) · Revista Española de Cardiología · doi:10.1016/s0300-8932(00)75104-9 · Cited by 39
The complex pathophysiology of cardiac cachexia: A review of current pathophysiology and implications for clinical practice
Thanapholsart, J., Khan, E., Ismail, T. F., & Lee, G. (2022) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2022.08.016 · Cited by 39
Lisinopril
Simpson, K. L., & Jarvis, B. (2000) · Drugs · doi:10.2165/00003495-200059050-00012 · Cited by 38
Efficacy and acceptability of perindopril in mild to moderate chronic congestive heart failure
Lechat, P. P., Garnham, S. P., Desché, P., & Bounhoure, J. (1993) · American Heart Journal · doi:10.1016/0002-8703(93)90933-z · Cited by 38
Angiotensin Receptor Blockers versus ACE Inhibitors: Prevention of Death and Myocardial Infarction in High-Risk Populations
Epstein, B. J., & Gums, J. G. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e478 · Cited by 38
Lisinopril Overdose and Management with Intravenous Angiotensin II
Trilli, L. E., & Johnson, K. A. (1994) · Annals of Pharmacotherapy · doi:10.1177/106002809402801006 · Cited by 38
Renin, Angiotensin II, and the Development of Effusions Following Bidirectional Glenn and Fontan Procedures
Mainwaring, R. D., Lamberti, J. J., Carter, T. L., Moore, J. W., & Nelson, J. C. (2010) · Journal of Cardiac Surgery · doi:10.1111/j.1540-8191.1995.tb01228.x · Cited by 38
Pharmacotherapy for Systolic Dysfunction: A Review of Randomized Clinical Trials
Gheorghiade, M., Benatar, D., Konstam, M. A., Stoukides, C. A., & Bonow, R. O. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00816-3 · Cited by 38
Simplified Echocardiography in the Diagnosis of Heart Failure
Willenheimer, R. B., Israelsson, B. A., Cline, C. M. J., & Erhardt, L. (1997) · Scandinavian Cardiovascular Journal · doi:10.3109/14017439709058063 · Cited by 38
Current medical therapy for advanced heart failure
Gheorghiade, M., Cody, R. J., Francis, G. S., McKenna, W. J., Young, J. B., & Bonow, R. O. (2000) · Heart & Lung · doi:10.1016/s0147-9563(00)90034-7 · Cited by 40
Self-citation
Cardiac vagal activity: a target for intervention in heart disease
Townend, J., & Littler, W. A. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90694-0 · Cited by 38
Chronic heart failure in the community: Missed diagnosis and missed opportunities
Akosah, K. O., Moncher, K., Schaper, A. M., Havlik, P., & Devine, S. (2001) · Journal of Cardiac Failure · doi:10.1054/jcaf.2001.26905 · Cited by 38
The Status of Hypertension Management in Japan in 2000.
Yamamoto, Y., Sonoyama, K., Matsubara, K., FURUSE, M., Yatsuhashi, T., Hamada, T., Oginö, K., Igawa, O., Hisatome, I., & Shigemasa, C. (2002) · Hypertension Research · doi:10.1291/hypres.25.717 · Cited by 38
Aldosterone and Aldosterone Antagonism in Cardiovascular Disease
Stier, C. T., Koenig, S., Lee, D. Y., Chawla, M. K., & Frishman, W. H. (2003) · Heart Disease · doi:10.1097/01.hdx.0000061698.20666.aa · Cited by 38
Critical review of heart failure: The role of left ventricular remodeling in the therapeutic response-Cohn: Remodeling in heart failure
Cohn, J. N. (1995) · Clinical Cardiology · doi:10.1002/clc.4960181603 · Cited by 38
Self-citation
Reverse remodeling in heart failure with intensification of vasodilator therapy
Levine, T. B., Levine, A. B., Keteyian, S. J., Narins, B., & Lesch, M. (1997) · Clinical Cardiology · doi:10.1002/clc.4960200806 · Cited by 38
Falling Cardiovascular Mortality in Heart Failure With Reduced Ejection Fraction and Implications for Clinical Trials
Rush, C. J., Campbell, R. T., Jhund, P. S., Connolly, E. C., Preiss, D., Gardner, R. S., Petrie, M. C., & McMurray, J. J. V. (2015) · JACC Heart Failure · doi:10.1016/j.jchf.2015.03.013 · Cited by 37
Specialist Care of Heart Failure Improves Appropriate Pharmacotherapy at the Expense of Greater Polypharmacy and Drug-Interactions
Ledwidge, M. T., Travers, B., Ryder, M., Ryan, E., & McDonald, K. (2004) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2003.08.003 · Cited by 37
Present Insights on Cardiomyopathy in Diabetic Patients
Felício, J. S., Koury, C. C., Carvalho, C. T., Neto, J. F. A., Miléo, K. B., Arbage, T. P., da Silva, D. D., de Oliveira, A. F., Peixoto, A. S., de Figueiredo, A. B., et al. (2015) · Current Diabetes Reviews · doi:10.2174/1573399812666150914120529 · Cited by 37
Long-term management of end-stage heart failure
Habal, M. V., & Garan, A. R. (2017) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2017.07.003 · Cited by 40
Effects of Combined Renin–Angiotensin–Aldosterone System Inhibitor and Beta-Blocker Treatment on Outcomes in Heart Failure with Reduced Ejection Fraction: Insights from BIOSTAT-CHF and ASIAN-HF Registries
Ouwerkerk, W., Teng, T. K., Tromp, J., Tay, W. T., Cleland, J. G. F., van Veldhuisen, D. J., Dickstein, K., Ng, L. L., Lang, C. C., Anker, S. D., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1869 · Cited by 37
Peripartum cardiomyopathy: Summary of an international survey on peripartum cardiomyopathy
Veille, J., & Zaccaro, D. J. (1999) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(99)70554-5 · Cited by 37
The treatment of coronary artery disease in patients with chronic kidney disease
Edwards, N. C., Steeds, R. P., Ferro, C. J., & Townend, J. (2006) · QJM · doi:10.1093/qjmed/hcl101 · Cited by 37
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) Developed in Collaboration With the American College of Chest Physicians and the International Society for Heart and Lung Transplantation
Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M. L., Konstam, M. A., MANCINI, D. M., Michl, K., et al. (2005) · Cited by 37
Self-citation
Diagnosis of patients with chronic heart failure in primary care: usefulness of history, examination, and investigations.
Khunti, K. K., Baker, R., & Grimshaw, G. (2000) · Europe PMC (PubMed Central) · Cited by 37
Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure
Sasayama, S., Asanoi, H., Kihara, Y., Yokawa, S., Terada, Y., Yoshida, S., Ejiri, M., & Horikoshi, I. (1994) · Heart and Vessels · doi:10.1007/bf01745236 · Cited by 37
Efficacy of Angiotensin Receptor Blockers in Cardiovascular Disease
Maggioni, A. P. (2006) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-006-9799-9 · Cited by 38
Acute Decompensated Heart Failure: A Contemporary Approach to Pharmacotherapeutic Management
McBride, B. F., & White, C. M. (2003) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.8.997.32873 · Cited by 37
Usefulness of Peak Oxygen Consumption in Predicting Outcome of Heart Failure in Women Versus Men
Richards, D. R., Mehra, M. R., Ventura, H. O., Lavie, C. J., Smart, F. W., Stapleton, D. D., & Milani, R. V. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00651-6 · Cited by 37
Predictors of improvement in left ventricular ejection fraction with carvedilol for congestive heart failure
O’Keefe, J. H., Magalski, A., Stevens, T. L., Bresnahan, D. R., Alaswad, K., Krueger, S. K., & Bateman, T. M. (2000) · Journal of Nuclear Cardiology · doi:10.1067/mnc.2000.102678 · Cited by 37
Prognostic value of plasma catecholamines, plasma renin activity, and plasma atrial natriuretic peptide at rest and during exercise in congestive heart failure: Comparison with clinical evaluation, ejection fraction, and exercise capacity
Madsen, B. K., Keller, N., Christiansen, E., & Christensen, N. J. (1995) · Journal of Cardiac Failure · doi:10.1016/1071-9164(95)90026-8 · Cited by 37
Beyond drug therapy: Nonpharmacologic care of the patient with advanced heart failure
Uretsky, B. F., Piña, I. L., Quigg, R. J., Brill, J. V., MacInerney, E. J., Mintzer, R., & Armstrong, P. W. (1998) · American Heart Journal · doi:10.1016/s0002-8703(98)70255-8 · Cited by 37
Angiotensin-converting enzyme inhibitor dosages in elderly patients with heart failure
Chen, Y., Wang, Y., Radford, M. J., & Krumholz, H. M. (2001) · American Heart Journal · doi:10.1067/mhj.2001.113227 · Cited by 37
Chapter 7. Anglotensln / Renln Modulators
Greenlee, W. J., & Siegl, P. K. S. (1992) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)60405-4 · Cited by 37
Destination Therapy With Left Ventricular Assist Devices: For Whom and When?
Porepa, L. F., & Starling, R. C. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.12.017 · Cited by 36
Nutrition and Heart Failure: Impact of Drug Therapies and Management Strategies
Dunn, S. P., Bleske, B. E., Dorsch, M. P., Macaulay, T. E., Tassell, B. W. V., & Vardeny, O. (2009) · Nutrition in Clinical Practice · doi:10.1177/0884533608329299 · Cited by 36
The Use of Midodrine in Patients With Advanced Heart Failure
Zakir, R. M., Folefack, A., Sarić, M., & Berkowitz, R. L. (2009) · Congestive Heart Failure · doi:10.1111/j.1751-7133.2008.00042.x · Cited by 36
Redox state, oxidative stress and endothelial dysfunction in heart failure: the puzzle of nitrate–thiol interaction
Parodi, O., Maria, R. D., & Roubina, E. (2007) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e32801194d4 · Cited by 37
Epidemiology, Pathophysiology, Prognosis, and Treatment of Systolic and Diastolic Heart Failure in Elderly Patients
Aronow, W. S. (2003) · Heart Disease · doi:10.1097/01.hdx.0000080714.87750.48 · Cited by 36
Effect of quinapril on blood pressure and heart rate in congestive heart failure
Townend, J., West, J. N. W., Davies, M. K., & Littler, W. A. (1992) · The American Journal of Cardiology · doi:10.1016/0002-9149(92)90708-7 · Cited by 36
ABC of heart failure: Management: diuretics, ACE inhibitors, and nitrates
Davies, M. K. (2000) · BMJ · doi:10.1136/bmj.320.7232.428 · Cited by 36
Peripartum cardiomyopathy: Current therapeutic perspectives
Phillips, S. D., & Warnes, C. A. (2004) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-004-0005-8 · Cited by 36
Reducing the Risk of Sudden Death in Heart Failure With β-Blockers
Adamson, P. B., & Gilbert, E. M. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.213 · Cited by 36
Cardioreparation and the Concept of Modulating Cardiovascular Structure and Function
Weber, K. T., Brilla, C. G., Cleland, J. G. F., Cohn, J. N., Hansson, L., Heagerty, A. M., Laragh, J. H., Laurent, S., Ollivier, J.-P., Pauletto, P., et al. (1993) · Blood Pressure · doi:10.3109/08037059309077521 · Cited by 36
Self-citation
Age‐Related Differences in Management of Heart Disease: A Study of Cardiac Medication Use in an Older Cohort
Ganz, D. A., Lamas, G. A., Orav, E. J., Goldman, L., Gutierrez, P. R., & Mangione, C. M. (1999) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1999.tb04571.x · Cited by 36
Is Beta-Blockade Useful in Heart Failure Patients with Atrial Fibrillation? An Analysis of Data from Two Previously Completed Prospective Trials
Fung, J. W., Chan, S. K. W., Yeung, L. Y. C., & Sanderson, J. E. (2002) · European Journal of Heart Failure · doi:10.1016/s1388-9842(02)00031-4 · Cited by 35

Authors: Cohn, J. N., Johnson, G., Ziesche, S., Cobb, F., Francis, G., Tristani, F., Smith, R., Dunkman, W. B., Loeb, H., Wong, M., Bhat, G., Goldman, S., Fletcher, R. D., Doherty, J., Hughes, C. V., Carson, P., Cintron, G., Shabetai, R., & Haakenson, C.
Affiliations: University of Minnesota (US)
ORCID: Cohn, Jay N.
Johnson, Gary
Bhat, Geetha
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1991-08
Volume: 325
Issue: 5
Pages: 303-310
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199108013250502
OpenAlex: W2046383587
Cited by: 2,833
References: 19
Citations by year: 2026: 14 · 2025: 15 · 2024: 26 · 2023: 21 · 2022: 31 · 2021: 27 · 2020: 46 · 2019: 39 · 2018: 51 · 2017: 56 · 2016: 69 · 2015: 59 · 2014: 54 · 2013: 61 · 2012: 56
FWCI: 124.25
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords: enalapril, hydralazine, isosorbide dinitrate, chronic congestive heart failure, vasodilator therapy, mortality, sudden death, exercise oxygen consumption, left ventricular ejection fraction, ACE inhibitors, combination therapy, digoxin, diuretics, NYHA functional class
MeSH terms: Adolescent, Adult, Aged, Chronic Disease, Death, Sudden, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Enalapril, Physical Exertion, Heart Failure, Hospitalization, Humans, Hydralazine, Isosorbide Dinitrate, Male, Middle Aged, Norepinephrine, Oxygen Consumption, Patient Compliance, Stroke Volume, Survival Rate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks